Neumora Therapeutics (NMRA) Competitors $1.76 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.74 -0.02 (-1.08%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. SYRE, UPB, STOK, VERV, PRAX, VALN, CRMD, MLYS, NUVB, and ORICShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Spyre Therapeutics (SYRE), Upstream Bio (UPB), Stoke Therapeutics (STOK), Verve Therapeutics (VERV), Praxis Precision Medicines (PRAX), Valneva (VALN), CorMedix (CRMD), Mineralys Therapeutics (MLYS), Nuvation Bio (NUVB), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Spyre Therapeutics Upstream Bio Stoke Therapeutics Verve Therapeutics Praxis Precision Medicines Valneva CorMedix Mineralys Therapeutics Nuvation Bio Oric Pharmaceuticals Neumora Therapeutics (NASDAQ:NMRA) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings. Which has more volatility and risk, NMRA or SYRE? Neumora Therapeutics has a beta of 2.91, suggesting that its share price is 191% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Do insiders & institutionals have more ownership in NMRA or SYRE? 47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by insiders. Comparatively, 15.4% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate NMRA or SYRE? Neumora Therapeutics presently has a consensus price target of $7.14, indicating a potential upside of 305.84%. Spyre Therapeutics has a consensus price target of $53.40, indicating a potential upside of 219.38%. Given Neumora Therapeutics' higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Does the media prefer NMRA or SYRE? In the previous week, Spyre Therapeutics had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 4 mentions for Spyre Therapeutics and 2 mentions for Neumora Therapeutics. Spyre Therapeutics' average media sentiment score of 1.33 beat Neumora Therapeutics' score of 1.19 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, NMRA or SYRE? Spyre Therapeutics has higher revenue and earnings than Neumora Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$243.79M-$1.57-1.12Spyre Therapeutics$890K1,134.71-$208.02M-$3.40-4.92 Is NMRA or SYRE more profitable? Spyre Therapeutics' return on equity of -71.30% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -98.95% -87.68% Spyre Therapeutics N/A -71.30%-38.69% SummarySpyre Therapeutics beats Neumora Therapeutics on 10 of the 14 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$285.02M$3.06B$5.77B$9.84BDividend YieldN/A2.26%3.95%4.03%P/E RatioN/A21.2231.3126.60Price / SalesN/A392.23467.16123.60Price / CashN/A44.4437.7659.36Price / Book1.568.0710.026.67Net Income-$243.79M-$54.08M$3.27B$265.59M7 Day Performance7.32%2.25%3.17%3.42%1 Month Performance-22.81%3.41%4.34%1.09%1 Year Performance-84.79%18.61%44.12%23.84% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.5765 of 5 stars$1.76flat$7.14+305.8%-84.8%$285.02MN/A0.00108Positive NewsSYRESpyre Therapeutics3.085 of 5 stars$16.94-0.1%$53.40+215.2%-38.4%$1.02B$890K-4.9873News CoveragePositive NewsUPBUpstream Bio2.3164 of 5 stars$18.02-4.8%$56.50+213.5%N/A$1.02B$2.37M0.0038STOKStoke Therapeutics4.4774 of 5 stars$18.51+1.6%$25.57+38.1%+39.1%$997.86M$36.56M21.78100VERVVerve Therapeutics2.7658 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110PRAXPraxis Precision Medicines1.7013 of 5 stars$46.63-1.0%$85.88+84.2%-12.3%$990.84M$8.55M-3.79110VALNValneva2.0786 of 5 stars$12.14+5.3%$15.50+27.7%+14.5%$981.14M$183.52M-12.39700Analyst ForecastGap UpCRMDCorMedix2.7102 of 5 stars$13.10+1.3%$16.71+27.6%+129.2%$965.21M$43.47M17.4730Positive NewsMLYSMineralys Therapeutics3.2601 of 5 stars$15.34+5.6%$32.25+110.2%+24.7%$962.61MN/A-4.3128Analyst ForecastNUVBNuvation Bio2.0552 of 5 stars$2.90+5.5%$7.33+152.9%-4.4%$941.25M$7.87M-4.6060News CoverageORICOric Pharmaceuticals4.7937 of 5 stars$9.90+2.5%$17.63+78.0%+2.7%$938.21MN/A-5.2480Positive NewsGap Down Related Companies and Tools Related Companies Spyre Therapeutics Competitors Upstream Bio Competitors Stoke Therapeutics Competitors Verve Therapeutics Competitors Praxis Precision Medicines Competitors Valneva Competitors CorMedix Competitors Mineralys Therapeutics Competitors Nuvation Bio Competitors Oric Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access